Tyra Biosciences (TYRA) Cash from Financing Activities (2020 - 2026)

Tyra Biosciences has reported Cash from Financing Activities for 7 years, with the latest figure at $160.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 7233.47% year-over-year to $160.4 million; the trailing twelve-month figure through Mar 2026 stood at $166.3 million (up 4048.07% YoY), and the FY2025 full-year result was $8.1 million, down 95.99% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $160.4 million, up from $4.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $200.3 million in Q1 2024, with the low at $3000.0 in Q4 2022.
• Historically, Cash from Financing Activities has averaged $21.9 million across 5 years, with a median of $467000.0 in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities sank 99.82% — and 2024, when it surged 53175.27%.
• Tyra Biosciences' Cash from Financing Activities stood at $3000.0 in 2022, then jumped by 10700.0% to $324000.0 in 2023, then jumped by 117.9% to $706000.0 in 2024, then soared by 563.31% to $4.7 million in 2025, then soared by 3324.79% to $160.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $160.4 million (Q1 2026), $4.7 million (Q4 2025), and $647000.0 (Q3 2025), per Business Quant data.